SCHEMBL17612200

SCHEMBL17612200

CC1[C@@H](OCCOCCOCCNC(=O)CCOCC(COCCC(=O)NCCOCCOCCO[C@H]2OC(COC(=O)c3ccccc3)[C@@H](C)[C@H](C)C2C)(COCCC(=O)NCCOCCOCCO[C@H]2OC(COC(=O)c3ccccc3)[C@@H](C)[C@H](C)C2C)NC(=O)OCc2ccccc2)OC(COC(=O)c2ccccc2)[C@@H](C)[C@@H]1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ NT5E P21589 1/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ KMT2A Q03164 3/20 0.32
▸ SLC6A2 P23975 1/20 0.32
▸ SLC6A3 Q01959 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ FGF1 P05230 5/20 0.32
▸ VEGFA P15692 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ FGF2 P09038 2/20 0.31
▸ BCHE P06276 1/20 0.31
▸ ACHE P22303 1/20 0.31
▸ GAA P10253 1/20 0.30
▸ RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9604438 0.93 LMNA (0.40) SMN1; SMN2LMNAL3MBTL1MAPTKMT2A
SCHEMBL9604566 0.88 SMN1; SMN2 (0.35) SMN1; SMN2LMNANT5EMAPTKMT2A
SCHEMBL16682389 0.88 LMNA (0.38) SMN1; SMN2LMNANT5EL3MBTL1KMT2A
SCHEMBL21101278 0.88 LMNA (0.38) SMN1; SMN2LMNANT5EL3MBTL1KMT2A
SCHEMBL2621427 0.86 SMN1; SMN2 (0.34) SMN1; SMN2KMT2ASLC6A3TDP1FGF1
SCHEMBL15829781 0.86 SMN1; SMN2 (0.34) SMN1; SMN2KMT2ASLC6A3TDP1FGF1
SCHEMBL9604567 0.86 SMN1; SMN2 (0.34) SMN1; SMN2KMT2ASLC6A3TDP1FGF1
SCHEMBL9604536 0.85 LMNA (0.39) SMN1; SMN2LMNAL3MBTL1
SCHEMBL10226175 0.83 LMNA (0.38) SMN1; SMN2LMNABCHEACHE
SCHEMBL9604519 0.81 TACR1 (0.35) SMN1; SMN2LMNABCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11666653-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2023-06-06 — — US disclosed
US-9867882-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2018-01-16 — — US disclosed
US-9370581-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2016-06-21 — — US disclosed
US-9370582-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2016-06-21 — — US disclosed
US-9352048-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2016-05-31 — — US disclosed
US-9290760-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2016-03-22 — — US disclosed
US-20150119445-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides BANK OF AMERICA, N.A. 2015-04-30 — — US disclosed
US-20150119444-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides BANK OF AMERICA, N.A. 2015-04-30 — — US disclosed
US-20150011615-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides BANK OF AMERICA, N.A. 2015-01-08 — — US disclosed
US-8828956-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2014-09-09 — — US disclosed
US-20130178512-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC (US) 2013-07-11 — — US disclosed
US-8450467-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2013-05-28 — — US disclosed
US-20120136042-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC (US) 2012-05-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178512-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES LPXN, ZYX, OSTC SMN1; SMN2 3506/4885LMNA 266/4885NT5E 2246/4885
US-20150119445-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides LPXN, ZYX, OSTC SMN1; SMN2 3469/4885LMNA 271/4885NT5E 2334/4885
US-11666653-B2 Carbohydrate conjugates as delivery agents for oligonucleotides HAVCR2, B3GAT3, CSGALNACT1 SMN1; SMN2 2980/4885LMNA 1934/4885NT5E 1725/4885
US-20150011615-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides LPXN, ZYX, OSTC SMN1; SMN2 3489/4885LMNA 274/4885NT5E 2230/4885
US-20150119444-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides LPXN, ZYX, OSTC SMN1; SMN2 3489/4885LMNA 274/4885NT5E 2230/4885
US-20120136042-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES LPXN, ZYX, OSTC SMN1; SMN2 3506/4885LMNA 266/4885NT5E 2246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback